The cost of relapse and the predictors of relapse in the treatment of schizophrenia

BMC Psychiatry

Volumn 10, Issue , 2010, Pages

  Ascher Svanum, Haya ^a   Zhu, Baojin ^a   Faries, Douglas E ^a   Salkever, David ^b   Slade, Eric P ^c,d   Peng, Xiaomei ^a   Conley, Robert R ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; FUNCTIONAL STATUS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH SERVICE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MENTAL HEALTH; MENTAL HEALTH CARE; ONSET AGE; PATIENT COMPLIANCE; PREVALENCE; RECURRENCE RISK; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; UNITED STATES; ADOLESCENT; AMBULATORY CARE; COMPARATIVE STUDY; DRUG COST; ECONOMICS; FEMALE; FOLLOW UP; MALE; PROBABILITY; PROPENSITY SCORE; PROSPECTIVE STUDY; PSYCHOLOGY; RECURRENT DISEASE; STATISTICS;

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGE OF ONSET; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; DRUG COSTS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; MEDICATION ADHERENCE; PROBABILITY; PROPENSITY SCORE; PROSPECTIVE STUDIES; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 76849096676     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-10-2     Document Type: Article

References (27)

1. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995, 21(3):419-429.
2. Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, Garcia P, Jeste DV. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004, 161(1):692-699. 10.1176/appi.ajp.161.4.692, 15056516.
3. Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004, 184:346-351. 10.1192/bjp.184.4.346, 15056580.
4. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001, 52(6):805-811. 10.1176/appi.ps.52.6.805, 11376229.
5. Andlin-Sobocki P, Jönsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol 2005, 12(Suppl 1):1-27. 10.1111/j.1468-1331.2005.01202.x, 15877774.
6. Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002, 40(8):630-639. 10.1097/00005650-200208000-00002, 12187177.
7. Weiden PJ. Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry 2007, 68(Suppl 14):14-19.
8. Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull 2008, 34(1):173-180. 10.1093/schbul/sbm061, 2632390, 17578893.
9. Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007, 23(10):2305-2312. 10.1185/030079907X226050, 17697454.
10. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006, 67(3):453-460. 10.4088/JCP.v67n0317, 16649833.
11. Salkever DS, Slade EP, Karakus MC. Employment retention by persons with schizophrenia employed in non-assisted jobs. J Rehabil 2003, 69(4):19-26.
12. Lehman AF, Fischer EP, Postrado L, Delahanty J, Johnstone BM, Russo PA, Crown WH. The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): an instrument to assess outcomes of schizophrenia care. Schizophr Bull 2003, 29(2):247-256.
13. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13(2):261-276.
14. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389. 10.1192/bjp.134.4.382, 444788.
15. Ware JE, Kosinski M, Keller SD. How to Score the SF-12? Physical and Mental Health Summary Scales 1998, Lincoln, RI: QualityMetric, 3.
16. Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RS, Swartz M, Perkins DO, Hsiao JK, Lieberman J. CATIE Study Investigators: Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006, 163(12):2080-2089. 10.1176/appi.ajp.163.12.2080, 17151158.
17. Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health 2006, 9(2):77-89. 10.1111/j.1524-4733.2006.00083.x, 16626411.
18. Hsiao WC, Braun P, Dunn D, Becker ER. Resource-based relative values. An overview. JAMA 1988, 260(16):2347-2353. 10.1001/jama.260.16.2347, 3050169.
19. Vaul JH. DRG benchmarking study establishes national coding norms. Healthc Financ Manage 1998, 52(52):54.
20. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998, 17(19):2265-2281. 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B, 9802183.
21. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004, 55(8):886-891. 10.1176/appi.ps.55.8.886, 15292538.
22. Law MR, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry 2008, 69(1):47-53. 10.4088/JCP.v69n0107, 18312037.
23. Welch WP. Medicare capitation payments to HMOs in light of regression towards the mean in health care costs. Advances in Health Economics and Health Services Research 1985, 6. Greenwich, CT: JAI Press, Scheffler RM, Rossiter LF.
24. Wrobel MV, Doshi J, Stuart BC, Briesacher B. Predictability of prescription drug expenditures for Medicare beneficiaries. Health Care Financ Rev 2003, 25(2):37-46.
25. Newhouse JP, Manning WG, Keeler EB, Sloss EM. Adjusting capitation rates using objective health measures and prior utilization. Health Care Financ Rev 1989, 10(3):41-54.
26. Donohue J. Mental health in the Medicare Part D drug benefit: a new regulatory model?. Health Aff (Millwood) 2006, 25(3):707-719. 10.1377/hlthaff.25.3.707, 16684735.
27. Salkever DS, Slade EP, Karakus M, Palmer L, Russo PA. Estimation of antipsychotic effects on hospitalization risk in a naturalistic study with selection on unobservables. J Nerv Ment Dis 2004, 192(2):119-128. 10.1097/01.nmd.0000110283.89270.23, 14770056.